Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222338 | 0.81 | SMN1; SMN2 (0.44) | ALDH1A1LMNAHSD17B10CA1CA2 | |
| SCHEMBL28126633 | 0.80 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10SMN1; SMN2 | |
| SCHEMBL27963792 | 0.77 | FAAH (0.31) | ALDH1A1LMNAHSD17B10FAAH | |
| SCHEMBL27944121 | 0.77 | ALDH1A1 (0.32) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL5145223 | 0.77 | TSHR (0.44) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL856078 | 0.76 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10SMN1; SMN2 | |
| SCHEMBL28474376 | 0.76 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10SMN1; SMN2 | |
| SCHEMBL28209617 | 0.76 | ALDH1A1 (0.36) | ALDH1A1LMNAHSD17B10CA1CA2 | |
| SCHEMBL27600925 | 0.76 | CA1 (0.39) | ALDH1A1LMNAHSD17B10CA1CA2 | |
| SCHEMBL29049226 | 0.74 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111072552-B | Preparation method of cilnidipine | 湖南九典制药股份有限公司 | 2021-06-04 | — | — | CN | claimed |
| CN-111875535-A | Nimodipine impurity IV reference substance and preparation method and application thereof | 湖南省药品检验研究院(湖南药用辅料检验检测中心) | 2020-11-03 | — | — | CN | claimed |
| CN-111072552-B | Preparation method of cilnidipine | 湖南九典制药股份有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-111875535-A | Nimodipine impurity IV reference substance and preparation method and application thereof | 湖南省药品检验研究院(湖南药用辅料检验检测中心) | 2020-11-03 | — | — | CN | disclosed |
| CN-111875535-A | Nimodipine impurity IV reference substance and preparation method and application thereof | 湖南省药品检验研究院(湖南药用辅料检验检测中心) | 2020-11-03 | — | — | CN | disclosed |
| CN-111072552-A | Preparation method of cilnidipine | 湖南九典制药股份有限公司 | 2020-04-28 | — | — | CN | disclosed |
| EP-1470108-B1 | 1,4-DIHYDROPYRIDINE AND PYRIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENT RES FOUNDATION (IN) | 2016-08-24 | — | — | EP | disclosed |
| EP-1542683-B1 | CALCIUM CHANNEL BLOCKERS | DIAKRON PHARMACEUTICALS INC (US) | 2013-01-09 | — | — | EP | disclosed |
| US-8106062-B1 | Calcium channel blockers | DIAKRON PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7235570-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH (IN) | 2007-06-26 | — | — | US | disclosed |
| US-20050159455-A1 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH (IN) | 2005-07-21 | — | — | US | disclosed |
| EP-1542683-A2 | CALCIUM CHANNEL BLOCKERS | Diakron Pharmaceuticals, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-6852742-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2005-02-08 | — | — | US | disclosed |
| EP-1470108-A1 | 1,4-DIHYDROPYRIDINE AND PYRIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2004-10-27 | — | — | EP | disclosed |
| WO-2004024153-A2 | CALCIUM CHANNEL BLOCKERS | DIAKRON PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| US-20040006110-A1 | To modulate the activity of calcium channels, therapy of cardiovascular disease or neurological disorders, that are associated with calcium channels | Knobbe, Martens, Olson & Bear, LLP | 2004-01-08 | — | — | US | disclosed |
| WO-2003062201-A1 | 1,4-DIHYDROPYRIDINE AND PYRIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006110-A1 | To modulate the activity of calcium channels, therapy of cardiovascular disease or neurological disorders, that are associated with calcium channels | RYR2, ORAI1, RYR1 | ALDH1A1 3124/4885LMNA 2226/4885HSD17B10 3744/4885 |
| US-20050159455-A1 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | RYR1, RYR2, ORAI1 | ALDH1A1 2429/4885LMNA 3055/4885HSD17B10 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.